Back to search

Article

Genetically proxied PDE5 inhibition and risk of dementia: a drug target Mendelian randomisation study

2024-02-15

Abstract excerpt

<h4>Background</h4> Phosphodiesterase-5 (PDE5) inhibitors have gained interest as a potential treatment for dementia. However, current evidence is limited to observational and pre-clinical studies. This drug- target Mendelian Randomisation (MR) study aims to elucidate the on-target effects of pharmacological PDE5 inhibition on dementia subtypes, cognitive traits, and neuro-imaging phenotypes. <h4>Methods</h4> Two...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
668d64e0-3bac-5aed-a1ad-3c3993b55cf4
DOI
10.1101/2024.02.15.24302874
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genetically proxied PDE5 inhibition and risk of dementia: a drug target Mendelian randomisation studyDOI 10.1101/2024.02.15.24302874
Repurposing drugs for the prevention of vascular dementia: Evidence from drug target Mendelian randomizationSemantic proximity
Evaluating the association between genetically proxied ACE inhibition and dementiasSemantic proximity
Causal insights of modifiable cardiovascular risk factors for dementia risk - potential for efficient prevention and improved brain health.Semantic proximity
Effect of genetically proxied use of PDE5 inhibitors on risk of CHD: A drug target Mendelian Randomization studySemantic proximity
Does blood pressure level matter more in individuals with higher genetic risk of dementia? A polygenic interaction study in the UK BiobankSemantic proximity
Hypertension and Dementia: A Mendelian Randomisation Study Assessing Potential Causal Relationships with All-Cause Dementia, Alzheimer’s Disease and Vascular Dementia in the UK BiobankSemantic proximity
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.Semantic proximity
Combining genetics with real-world patient data enables ancestry-specific target identification and drug discovery in Alzheimer’s diseaseSemantic proximity
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.Semantic proximity
High Blood Pressure and Risk of Dementia: A Two-Sample Mendelian Randomization Study in the UK BiobankSemantic proximity
Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart–Brain AxisSemantic proximity
Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization StudySemantic proximity
Select a neighboring publication to make it the new centre.